About Ducentis BioTherapeutics

About company

Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Our target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory disease affecting the lung, liver, kidney, eye, bone and cartilage.